Rahim Kanji

Dr. Rahim Kanji

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
YGYing Gue
Ying Gue
MSMax Sayers
Max Sayers
BWBenjamin T. Whitby
Benjamin T. Whitby
RKRahim Kanji
Rahim Kanji
KAKrishma Adatia
Krishma Adatia
DGDiana Gorog
Diana Gorog

9 December 2020 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RKRahim Kanji
Rahim Kanji
JKJacek Kubica
Jacek Kubica
ENEliano P. Navarese
Eliano P. Navarese
DGDiana Gorog
Diana Gorog
The development of an obstructive luminal thrombus is pathological and considered a failure of endogenous fibrinolysis. The consequences may be fatal, or result in lasting downstream organ damage. Therefore, assessment of endogenous fibrinolytic status in an individual may identify those at risk of occlusive thrombus formation and provide prognostic information. Arterial thrombi are more platelet rich and more resistant to fibrinolysis than venous thrombi. Several recent studies using global tests of fibrinolysis in patients with acute coronary syndromes (ACS) have shown that despite dual antiplatelet therapy, patients with impaired fibrinolytic status have an increased risk of adverse cardiovascular events, compared with those with effective fibrinolytic function. Such data add significantly to the predictive value of established cardiovascular risk factors and conventional biomarkers. Most data reported have been obtained with the Global Thrombosis Test and the turbidimetric plasma clot lysis assay. A few small studies in patients with ischaemic stroke suggest a similar predictive role of fibrinolytic status assessment in these patients. Studies reporting an association between impaired fibrinolysis and future venous thrombotic events are limited, and in the form of case‐control studies. Viscoelastic assays may have a role in the prediction of venous thromboembolic risk. Assays of fibrinolytic function should be used to obtain a more accurate risk of future thrombotic events, particularly in the setting of ACS. The availability of point‐of‐care tests helps facilitate this and should encourage future studies to assess personalised antithrombotic treatment combinations to optimise fibrinolytic status and reduce thrombosis risk.

Verified
Journal Article
Open access
PDF file
RKRahim Kanji
Rahim Kanji
YGYing Gue
Ying Gue
VMVassilios Memtsas
Vassilios Memtsas
DGDiana Gorog
Diana Gorog
The extent and duration of occlusive thrombus formation following an arterial atherothrombotic plaque disruption may be determined by the effectiveness of endogenous fibrinolysis. The determinants of endogenous fibrinolysis are the subject of much research, and it is now broadly accepted that clot composition as well as the environment in which the thrombus was formed play a significant role. Thrombi with a high platelet content demonstrate significant resistance to fibrinolysis, and this may be attributable to an augmented ability for thrombin generation and the release of fibrinolysis inhibitors, resulting in a fibrin-dense, stable thrombus. Additional platelet activators may augment thrombin generation further, and in the case of coronary stenosis, high shear has been shown to strengthen the attachment of the thrombus to the vessel wall. Neutrophil extracellular traps contribute to fibrinolysis resistance. Additionally, platelet-mediated clot retraction, release of Factor XIII and resultant crosslinking with fibrinolysis inhibitors impart structural stability to the thrombus against dislodgment by flow. Further work is needed in this rapidly evolving field, and efforts to mimic the pathophysiological environment in vitro are essential to further elucidate the mechanism of fibrinolysis resistance and in providing models to assess the effects of pharmacotherapy.

1 September 2020 in Structural Heart
Verified
Journal Article
Open access
RKRahim Kanji
Rahim Kanji
SMSaeed Mirsadraee
Saeed Mirsadraee
SPSanjay Prasad
Sanjay Prasad
YGYing X. Gue
Ying X. Gue
VPVasileios Panoulas
Vasileios Panoulas
DGDiana Gorog
Diana Gorog
The introduction of transcatheter aortic valve implantation (TAVI) has revolutionised the management of aortic stenosis (AS), with procedure numbers rapidly increasing. Although there has been enthusiastic roll-out of TAVI to increasingly low surgical-risk patients, there are still a number of factors pertaining to this new technology that are incompletely understood. Important unknowns include the real stroke risk associated with TAVI, which extends beyond the periprocedural window; the risk of subclinical valve thrombosis (SCVT); valve degeneration; and the optimal antithrombotic regimen peri- and post-TAVI to minimise these potential complications. Whilst operator experience and improvement in TAVI technology has resulted in significant reduction in peri-procedural cerebrovascular ischaemic events, a greater understanding is required of the pathophysiology of the underlying stroke-risk beyond the peri-operative period. Procedure-related, patient-related and valve-related factors may predispose to stroke post-TAVI. There is increasing appreciation of the occurrence of SCVT post-TAVI, but the clinical significance of this is unclear. Whilst oral anticoagulation can achieve resolution of SCVT, there are important concerns about bleeding with routine anticoagulation, and treatment with dual antiplatelet therapy appears to confer no incremental benefit when compared to single antiplatelet therapy, whilst conferring a higher bleeding risk. In this review, we discuss the incidence, aetiology and clinical significance of TAVI-related thrombosis and how this is affected by antithrombotic therapies.